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A B S T R A C T
Aims: Perinatal asphyxia (PA) often results in hypoxic–ischemic encephalopathy (HIE) in term neonates.
Introduction of therapeutic hypothermia improved HIE outcome, but further neuroprotective therapies are still
warranted. The present study sought to determine the feasibility of the activation of the cytoprotective PI-3-K/
Akt and the MAPK/ERK signaling pathways in the subacute phase of HIE development in a translational new-
born pig PA/HIE model.
Main methods: Phosphorylated and total levels of Akt and ERK were determined by Western blotting in brain
samples obtained from untreated naive, time control, and PA/HIE animals at 24–48 h survival (n= 3–3–6,re-
spectively). PA (20 min) was induced in anesthetized piglets by ventilation with a hypoxic/hypercapnic (6%
O220%CO2) gas mixture. Furthermore, we studied the eﬀect of topically administered speciﬁc Akt1/2 and
MAPK/ERK kinase inhibitors on Akt and ERK phosphorylation (n= 4–4) in the cerebral cortex under normoxic
conditions.
Key ﬁndings: PA resulted in signiﬁcant neuronal injury shown by neuropathology assessment of haematoxylin/
eosin stained sections. However, there were no signiﬁcant diﬀerences among the groups in the high phos-
phorylation levels of both ERK and Akt in the cerebral cortex, hippocampus and subcortical structures. However,
the Akt1/2 and MAPK/ERK kinase inhibitors signiﬁcantly reduced cerebrocortical Akt and ERK phosphorylation
within 30 min.
Signiﬁcance: The major ﬁnding of the present study is that the PI-3-K/Akt and the MAPK/ERK signaling path-
ways appear to be constitutively active in the piglet brain, and this activation remains unaltered during HIE
development. Thus, neuroprotective strategies aiming to activate these pathways to limit apoptotic neuronal
death may oﬀer limited eﬃcacy in this translational model.
1. Introduction
According to the World Health Organization's estimates, perinatal
asphyxia (PA) aﬀects 4 neonates out of 1000 live births [1]. The neu-
ronal injury triggered by PA may lead to the so-called hypoxic-ischemic
encephalopathy (HIE) in the survivors leading to lifelong neurodeve-
lopmental disorders. The neuronal injury eliciting HIE is no longer
considered as a single “event” during PA but rather an evolving process
that lasts for days after the resolution of the asphyxia. Correspondingly,
mild whole body hypothermia applied in the ﬁrst 2–3 days after PA is
currently the only eﬀective therapy to mitigate HIE severity [2].
However, hypothermia cannot cure HIE alone, and thus clearly further
therapies are needed that can augment the neuroprotection aﬀorded by
cooling.
The newborn piglet is an established large animal model of the term
neonate because of its gyrencephalic brain, developmental stage, body
size, cerebrovascular regulation and its cerebral glucose metabolic rate
are similar to the term human neonate [3]. We have recently created
and characterized a piglet PA/HIE model that resulted in moderate/
severe brain damage in most of the animals [4]. This model faithfully
reproduces all major hallmarks of human PA/HIE, and can be used to
assess the molecular mechanisms of HIE development, and to identify
appealing targets for neuroprotective interventions. One of these may
be the brain-derived neurotrophic factor (BDNF) signaling pathway.
BDNF is a member of the neurotrophic factor family that plays an im-
portant role in regulating neural proliferation, diﬀerentiation and sur-
vival [5,6]. The neuroprotective actions of BDNF are mediated through
the phosphatidylinositide 3-kinases (PI-3-K) and the mitogen-activated
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protein kinase (MAPK) pathways [7]. The PI-3-K pathway activates the
kinase Akt, one of its direct downstream protein kinase eﬀectors, which
regulates multiple biological processes including cell survival, pro-
liferation, growth, and glycogen metabolism [8,9]. Similarly, MAPK-s
also regulates widespread cellular processes including cell survival, and
apoptosis. Extracellular signal-regulated kinase (ERK) is an anti-
apoptotic MAPK, as its downstream pathways are usually linked to
growth factor action: cellular diﬀerentiation and proliferation. Thus,
ERK usually promotes cell survival [10]. Maintaining the delicate bal-
ance between the simultaneously active and inactive kinases is critical
in determining cell fate [11]. There are both in vitro and in vivo studies
providing evidence that BDNF-supported neuronal survival is mediated
via the activation of the ERK pathway [12,13], while others have shown
that rather the PI-3-K pathway is involved [14]. Therefore, it appears
that growth factor-mediated protection of neurons can occur via dif-
ferent pathways depending on various factors such as cell types, en-
vironmental conditions, and cellular stimuli. However, the potential in
vivo role of these pathways in the neuronal injury/survival during HIE
has not yet been previously studied in a PA/HIE large animal model.
Therefore, the major objective of the present study was to determine
the in vivo activation of the PI-3-K/Akt and the MAPK/ERK signaling
pathways under normoxic conditions and over the course of HIE de-
velopment (24–48 h). The results emanating from these studies urged
us to test also if cortical kinase activities can be in vivo modiﬁed by
speciﬁc inhibitors.
2. Materials and methods
2.1. Experimental groups
All necessary permits to perform the in vivo animal experiments
including the approval from the Institutional Animal Care and Use
Committee have been obtained preceding the experiments. Animal care
and handling were in accordance with the National Institutes of Health
guidelines. The levels of activated ERK and Akt kinases have been de-
termined in the following experimental groups (Fig. 1): (1) untreated
animals without any interventions (n= 3); (2) normoxic time controls
(n= 3) with 24 or 48 h of survival (n= 1–2, respectively); (3) animals
undergoing 20 min PA (n= 6) also with 24 or 48 h of survival
(n= 3–3, respectively); (4) non-asphyxiated animals treated topically
with the MAPK/ERK kinase (MEK) inhibitor U0126 monoethanolate
(n= 4); and (5) non-asphyxiated animals treated topically with the
Akt1/2 kinase inhibitor A-6730 (n= 4) onto the cerebral cortex. The
detailed procedures applied to the diﬀerent groups are given in the
subsequent paragraphs.
2.2. Animals
Newborn (< 24 h old) male Large-White piglets (weighing between
1.5 and 2.5 kg, n= 20) were used in the present study, they were de-
livered to the laboratory on the morning of the experiments from a local
company (Pigmark Ltd., Co., Szeged, Hungary). The animals were an-
esthetized with an intraperitoneal injection of sodium thiopental
(45 mg/kg; Sandoz, Kundl, Austria). The animals were placed on a
heating pad. The skin was disinfected, and the animals were intubated
through a tracheotomy. Then the piglets were artiﬁcially ventilated
with warmed, humidiﬁed medical air (21% O2, balance N2) at a fre-
quency of 30–35 breaths/min, using a pressure controlled ventilator
applying peak inspiratory pressure = 120–135 mmH2O. Aseptic tech-
nique was followed during all aspects of the animal surgery. With the
exception of the untreated animals, the right carotid artery and femoral
vein were cannulated with catheters. To maintain anesthesia/analgesia
the mechanically ventilated animals were given a bolus injection of
morphine (100 μg/kg; Teva, Petach Tikva, Israel) and midazolam
(250 μg/kg; Torrex Pharma, Vienna, Austria), then were infused with
morphine (10 μg/kg/h), midazolam (250 μg/kg/h) and ﬂuids (5%
glucose, 0.45% NaCl 3–5 ml/kg/h) throughout the whole experiment.
The wounds were closed and covered with warm compress to minimize
heat and ﬂuid losses.
2.3. Experimental PA/HIE
The piglets between the time control and the asphyxia groups were
randomized with coin ﬂip. The animals were placed into a neonatal
incubator (SPC 78-1; Narco Air-Shields, Inc., Hatboro, Pa., USA).
Oxygen saturation, mean arterial blood pressure (MABP) through the
arterial catheter, heart rate (HR), and ECG were continuously mon-
itored using a Hewlett-Packard M1094 monitor (Palo Alto, California,
USA) and recorded online (MecifView, Arlington, Mass., USA). Core
temperature was maintained rigorously between 38.5 ± 0.5 °C with a
servo-controlled heating pad. Prophylactic antibiotics were given in-
travenously (penicillin: 50 mg/kg/12 h, Teva, Petah Tikva, Israel and
gentamicin: 2.5 mg/kg/12 h, Sanoﬁ, Paris, France) and the urinary
bladder was tapped by suprapubic puncture every 12 h of survival.
Arterial blood gases, along with blood sugar and lactate levels were
determined (~300 μl/sample; EPOC Blood Analysis, Epocal Inc.,
Ottawa, Canada) at deﬁned intervals to monitor the eﬀect of PA and to
keep the values in their respective physiological ranges during the
Fig. 1. Experimental protocol. Untreated animals
served as naïve controls; Control animals were an-
esthetized, ventilated, and monitored, but not sub-
jected to asphyxia. Asphyxia animals were like
Controls but were exposed to 20 min asphyxia. The
animals in the MEK and Akt1/2 kinase inhibitor
groups were ﬁtted with closed cranial windows and
the respective drugs were applied locally onto the
cerebral cortex.
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survival period.
PA was induced by ventilation with a hypoxic/hypercapnic gas
mixture containing 6% O2 and 20% CO2 for 20 min while respiratory
rate was reduced from 30 to 15 breaths/min, and intravenous glucose
administration was suspended. Arterial blood gases were also de-
termined to check the severity of PA at the end of asphyxia (blood
sample was taken at the 18th min of asphyxia). Reventilation was
commenced with medical air throughout the survival period.
2.4. The study of ERK and Akt kinase inhibitors
In these groups, the head of the anesthetized, mechanically venti-
lated animals were ﬁxed in a stereotactic frame. Monitoring of phy-
siological parameters was similar to the previous groups. After retrac-
tion of the scalp, a circular craniotomy was made in the left
frontoparietal region, where after careful removal of the dura mater, a
stainless steel closed cranial window with three needle ports was in-
serted. The cranial window was sealed with bone wax, cemented in
place with dental acrylic, and was ﬁlled with artiﬁcial cerebrospinal
ﬂuid (aCSF; containing KCl 220 mg/l, MgCl2 132 mg/l, CaCl2 221 mg/l,
NaCl 7710 mg/l, urea 402 mg/l, dextrose 665 mg/l, and NaHCO2
2066 mg/l, warmed to 37 °C and equilibrated with a gas mixture con-
taining 6% O2, 6.5% CO2 and 87.5% N2). There was a 45 min stabili-
zation period allowed after the implantation of the cranial window
before commencing the experiments.
Both the MEK inhibitor U0126 and the Akt1/2 kinase inhibitor A-
6730 drugs were prepared similarly: ﬁrst a 10 mM stock solution was
produced in dimethyl-sulfoxide (DMSO) that was further diluted in
aCSF to obtain 10 μM drug solutions (ﬁnal DMSO concentration was
0.01%). In the respective experimental groups, the drugs were applied
topically onto the cerebral cortex with continuous superfusion through
one of the injectable ports at a rate of 0.5 ml/min for 40 min. The other
two ports allowed continuous eﬄux of the aCSF. Immediately after the
completion of the drug treatment, the animals were euthanized with
300 mg Na-pentobarbital (Release®, WDT, Garbsen, Germany). The
cortex below the cranial window as well as the corresponding con-
tralateral untreated cortex were collected and processed as described in
the following section.
2.5. Western blot analysis
At the end of the respective experimental periods (Fig. 1), both
carotid arteries were catheterized in the distal direction, and the brains
were perfused through them with cold (4 °C) physiological saline. The
brains were gently removed from the skull, and tissue samples were
snap frozen in liquid N2, and stored at −80 °C before Western-blot
analysis.
Thawed samples were homogenized and harvested in ice-cold lysis
buﬀer (50 mM Tris-base, pH 7.4, 150 mM NaCl, 10% glycerol, 1 mM
EGTA, 1 mM Na-orthovanadate, 5 μM ZnCl2, 100 mM NaF, 10 μg/ml
aprotinin, 1 μg/ml leupeptin, 1 mM phenylmethylsulfonyl ﬂuoride
(PMSF), 1% Triton X-100). The homogenate was centrifuged at
40,000 ×g at 4 °C for 30 min and the protein concentration of the su-
pernatant was determined (Bio-Rad Protein Assay Dye Reagent
Concentrate, Bio-Rad, Hercules, CA, USA).
Samples prepared from equal amounts (50 μg) of protein were
mixed with Laemmli buﬀer (1 M Tris-HCl, pH 6.8, glycerol, SDS,
100 mM EDTA, 100 mM EGTA and 1% bromophenol blue) and dena-
tured by boiling. Subsequently, they were loaded for 12% SDS-con-
taining polyacrylamide gel and separated based on molecular size. The
gels were electroblotted for polyvinylidene diﬂuoride (PVDF) mem-
branes (Hybond-P, GE Healthcare, United Kingdom).
Detection of the protein of interest was carried out by ﬁrst blocking
the membrane in 3% nonfat dry milk in Tris Buﬀered Saline -Tween
(10 mM Tris-base, 150 mM NaCl, 0.2% Tween-20, pH 8.0; TBS-Tween).
Membranes were probed overnight at 4 °C with antibodies recognizing
the following antigens: phospho-p44/42 MAP kinase to detect phospho-
ERK1/2, total p44/42 MAP kinase, anti-Akt and phospho-Akt (Ser473),
(Cell Signaling Technology, Danvers, MA, USA), diluted 1:1000 in the
blocking solution. Excess antibody was removed by ﬁve washes of TBS-
Tween. Membranes were incubated with a horseradish-peroxidase
(HRP)-conjugated goat anti-rabbit secondary antibody (Cell Signaling
Technology, Danvers, MA, USA) diluted 1:1000 in blocking solution at
room temperature for 2 h. Five washes in TBS-Tween were followed by
detection of the enhanced chemiluminescent signal (WesternBright
ECL, Advansta, USA) on X-ray ﬁlms. The relative protein expressions
were determined using densitometry (ImageJ software, National
Institutes of Health, USA). Each experiment has been performed at least
three times. Values are expressed as mean ± S.E.M.
2.6. Histology
Brain samples collected for histology were immersion-ﬁxed in 4 °C,
4% paraformaldehyde solution for two weeks then processed further.
From the cerebral cortex, paraﬃn embedded 4 μm sections were
stained with haematoxylin-eosin. The slides were evaluated by two
independent researcher blinded to the experimental protocol with light
microscopy (Leica Microsystems, Wetzlar, Germany). The degree of
cerebrocortical neuronal damage in the frontoparietal region was
graded on a 10-step scale from 0 to 9 using our previously established
scoring system [15,4]. Brieﬂy, four pattern of neuronal injury (none;
scattered; grouped; panlaminar) was determined in 20–20 non-over-
lapping ﬁelds of vision in the frontal region. Then, ﬁnal score (0–9)
were given to the region based on the most severe level of damage seen
for a particular region.
2.7. Statistical analysis
Results were plotted using SigmaPlot (v12.0, Systat Software Inc.,
San Jose, CA., USA). Core temperature, saturation, HR and MABP as
well as arterial blood gas and metabolic parameters were expressed as
mean ± S.E.M.
Statistical comparisons include one-way analysis of variance
(ANOVA) as well as two-way repeated measures ANOVA followed by
the Holm-Sidak post-hoc test for pairwise comparisons. Neuropathology
scores were expressed as median, 25–75 percentiles. For non-para-
metric data Mann-Whitney U test was applied. p values< 0.05 were
considered to be signiﬁcant.
3. Results
3.1. In vivo observations
At the beginning of the experiments, piglets in both the control and
the asphyxia group had similar, physiological values of core tempera-
ture (38.6 ± 0.1 and 38.6 ± 0.1 °C), oxygen saturation (91 ± 3 and
97 ± 3%), heart rate (133 ± 10 and 150 ± 14 1/min), and MABP
(68 ± 7 and 65 ± 9 mmHg), respectively. Also, arterial blood pH,
blood gases and metabolites were similar and within the normal range
for these and the untreated group as well (Table 1).
Asphyxia elicited marked increases in HR and MABP (peak values
were 200 ± 60 1/min and 94 ± 18 mmHg, respectively) and large
drop in oxygen saturation (to 27 ± 1%). Correspondingly, the blood
gas analysis performed at the end of the asphyxia period revealed se-
vere hypoxemia, acidosis due to both hypercapnia and elevated blood
lactate levels, and hyperglycemia (Table 1). Reventilation restored
oxygenation quickly, and the assessed physiological parameters all re-
turned toward baseline levels and they were not then statistically dif-
ferent from the corresponding values of the control group with the
exception of blood glucose and lactate levels. These remained sig-
niﬁcantly elevated at 1 h of reventilation but then returned to baseline
values by 4 h of reventilation. (Fig. 2, Table 1). Then, the assessed
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physiological parameters remained in the respective physiological
ranges and were statistically not diﬀerent from the time control group
during the rest of the survival period.
3.2. Neuropathology
Asphyxia resulted in severe neuronal damage similar to previously
reported values conﬁrming HIE development. In the frontoparietal
cortex, the neuropathology scores were signiﬁcantly higher as com-
pared to the values of the normoxic (combined untreated/time control
animals) groups: the scores were 7; 6; 8 versus 1; 1; 4 *(median;
25th;75th percentiles; asphyxiated versus normoxic animals, respec-
tively; n= 5–5, *p= 0,008, Mann-Whitney U test).
3.3. Activation of ERK/Akt signaling pathways
Total ERK levels in the frontoparietal cortex were remarkably si-
milar in all experimental groups. In addition, the levels of phosphory-
lated ERK (P-ERK) were also similar to the total levels; therefore the
ratio of the P-ERK to total ERK was typically between 80 and 100%
indicating high degree of activation of the pathway (Fig. 3.) The results
concerning total and phosphorylated Akt (P-Akt) levels, the ratio of P-
Akt to total Akt levels were remarkably high and there were no statis-
tical diﬀerences among the groups, despite a slight tendency of acti-
vation by asphyxia (Fig. 3.)
High degree of ERK and Akt phosphorylation in the frontoparietal
cortex was also demonstrated in the samples taken from the control side
in our short-term experiments (Fig. 4). However, under normoxic
conditions, local, topical in vivo treatment with the MEK inhibitor
U0126 and the Akt1/2 kinase inhibitor A-6730 resulted in signiﬁcant
inhibition of ERK and Akt phosphorylation, respectively (Fig. 4).
The ratios of P-ERK/total ERK and the P-Akt/total Akt in the other
assessed brain regions were remarkably similar to the values de-
termined in the neocortex (Fig. 5). In the untreated as well as in the
48 h asphyxia animals, the phosphorylation ratios were remarkably
high and there were no statistical diﬀerences among the groups, in-
dicating no eﬀect of asphyxia.
4. Discussion
The most important novel ﬁndings of the present study are the
following: (1) we could assess activation levels of two signaling path-
ways important for neuronal survival in a large animal model of HIE;
(2) we found that both ERK and Akt are constitutively phosphorylated/
active in the cerebral cortex and all other assessed brain regions of
newborn pigs irrespective of the length of anesthesia and/or exposure
to asphyxia; (3) we proved that the high cerebrocortical ERK and Akt
phosphorylation levels under normoxic conditions can be in vivo
modulated by speciﬁc inhibitors.
The pathophysiology of HIE is not yet fully understood, however, in
recent years the neuronal injury during HIE is increasingly being
viewed as a multi-step process consisting of distinct pathomechanisms
characteristic of the successive phases of HIE development. These
phases include (1) the primary energy failure during the PA stress, (2)
the reoxygenation/reperfusion injury associated with the reventilation/
resuscitation eﬀorts, and (3) the so-called “secondary energy failure”
triggered perhaps by accumulated mitochondrial damage and asso-
ciated clinically with bouts of apnoe periods and seizures [16]. During
the primary energy failure of PA, the lack of oxygen and the reduction
of blood ﬂow shifts cellular metabolism from an aerobic to a less
Table 1
Arterial blood gas and metabolite analysis in the diﬀerent groups. Arterial blood pH, partial pressures of carbon dioxide, partial pressures of oxygen, as well as blood glucose- and lactate
levels were in the normal ranges at baseline conditions in all three groups. Asphyxia resulted in severe hypoxemia, hypercapnia, acidosis, hyperglycemia and elevations in lactate
indicating severe mixed respiratory and metabolic acidosis. Reventilation quickly restored blood gases, however, and blood sugar and lactate levels were still elevated at 1 h compared to
controls, and normalized only by 4 h after reventilation. The values then remained in the physiological range and there was no diﬀerence between the experimental groups at any later
time points (data beyond 20 h are not shown). Data are shown as mean ± S.E.M. Level of signiﬁcance (p) was set at 0.05. *vs. baseline; †vs. asphyxia at given time point.
Arterial pH Base Asph. 1 h 4 h 8 h 12 h 16 h 20 h
Untreated 7.55 ± 0.09
Control 7.51 ± 0.04 NA 7.51 ± 0.04 7.49 ± 0.02 7.5 ± 0.1 7.52 ± 0.07 7.54 ± 0.09 7.53 ± 0.08
Asphyxia 7.55 ± 0.05 6.87 ± 0.01⁎ 7.47 ± 0.06 7.51 ± 0.06 7.31 ± 0.42 7.49 ± 0.08 7.48 ± 0.11 7.53 ± 0.04
Arterial pCO2 (mmHg) Base Asph. 1 h 4 h 8 h 12 h 16 h 20 h
Untreated 35.3 ± 8.9
Control 37.1 ± 6 NA 39.7 ± 7.3 43.3 ± 4.4 41.7 ± 14.2 39.2 ± 13.6 37.7 ± 8.2 38.6 ± 7.7
Asphyxia 36.5 ± 4.6 164.3 ± 31⁎ 35.1 ± 5.4 41.4 ± 6.3 37.4 ± 17.6 38.8 ± 7.9 43.1 ± 12.5 40.8 ± 16.2
Arterial pO2 (mmHg) Base Asph. 1 h 4 h 8 h 12 h 16 h 20 h
Untreated 76.7 ± 17.4
Control 52.9 ± 4 NA 52.5 ± 5.9 58.4 ± 7.9 52.5 ± 2.4 51.3 ± 2.8 53.1 ± 4 53.8 ± 2.2
Asphyxia 63.5 ± 9.6 20 ± 6.2⁎ 60.4 ± 7.7 60.9 ± 10.5 58.6 ± 9.4 60 ± 7.2 65.8 ± 5.3 70.3 ± 7.8
Blood glucose (mmol/l) Base Asph. 1 h 4 h 8 h 12 h 16 h 20 h
Untreated 5.5 ± 1.9
Control 5.3 ± 0.2 NA 4.8 ± 0.9 5.7 ± 1.7 5.5 ± 2.4 4.3 ± 2.1 4.5 ± 0.7 5.1 ± 0.8
Asphyxia 5.8 ± 0.9 9 ± 1.2⁎ 7.3 ± 1.1⁎ 5.6 ± 0.6 4.1 ± 0.8⁎ 4.6 ± 0.9⁎ 4.7 ± 0.9⁎ 4.6 ± 0.8⁎
Blood lactate (mmol/l) Base Asph. 1 h 4 h 8 h 12 h 16 h 20 h
Untreated 2 ± 1.3
Control 2.2 ± 0.8 NA 1.2 ± 0.1 1.1 ± 0.4 1.3 ± 0.7 1.3 ± 0.7 1.5 ± 1 1.5 ± 0.6
Asphyxia 1.6 ± 0.7 7.4 ± 0.7⁎ 7.7 ± 2.2⁎,† 1.5 ± 0.6 1.2 ± 0.5 1.2 ± 0.4 1.1 ± 0.4 1.1 ± 0.3
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eﬃcient anaerobic pathway, resulting in the depletion of NAD+ stores,
decrease in ATP levels, and lactate accumulation [17]. ATP depletion
will soon lead to the depression of neuronal activity soon followed by
anoxic depolarization. Anoxic depolarization is characterized by the
loss of transmembrane ionic gradients eliciting the accumulation of
intracellular Na+, H+, and Ca2+ ions causing edema and worsening
tissue acidosis [18,19], the unregulated release of excitatory amino
acids along with the inhibition of astrocytic uptake can also contribute
to excitotoxic damage via the N-methyl-D-aspartate (NMDA) receptor
[20,21]. Upon reventilation/reoxygenation, the high energy phosphate
levels and the transmembrane ionic gradients are gradually restored,
but the initially still increased intracellular and intramitochondrial
Ca2+ levels will activate a host of intracellular proteases and nucleases,
as well as enzymatic and non-enzymatic synthesis of reactive oxygen
species (ROS). These alterations will trigger mitochondrial dysfunction
[17] and DNA fragmentation [22] setting the stage for further delayed
and programmed neuronal cell death during the secondary energy
failure stage. Based on the above delineated sequence of events, ra-
tional neuroprotective therapies aimed to mitigate neuronal injury of
HIE should focus on (1) shortening the duration of asphyxia, (2) ad-
ministration of cytoprotective/antioxidant agents simultaneously with
the resuscitation to limit reoxygenation/reperfusion injury, and (3) to
implement neuroprotective interventions before the neuronal injury
related to secondary energy failure occurs. These options can and
should be combined to maximize their neuroprotective potential, but
perhaps the third option has the largest translational feasibility as there
is usually a latent phase between the restoration of brain energy me-
tabolism upon reoxygenation and the onset of secondary energy failure
that oﬀers at least a 5–6 h long therapeutic window for interventions.
In the current experiments, we used a large animal (piglet) PA/HIE
model that was previously characterized [4] and now conﬁrmed to
present all the major metabolic hallmarks of PA also observed in hu-
mans at birth (hypoxemia, hypercapnia and lactic acidosis), and to
develop HIE shown by neuropathology scores. This model has been
successfully implemented to show neuroprotection aﬀorded by re-
ventilation with gas mixture containing 2.1% molecular hydrogen,
likely mitigating the oxidative stress-induced neuronal damage asso-
ciated with reoxygenation/reperfusion [4]. Another attractive neuro-
protective target would be the prevention of neuronal cell death
through the activation of antiapoptotic signaling pathways. This ap-
proach could be used in the latent phase after reoxygenation but before
the onset of secondary energy failure as although necrosis can be ob-
served within minutes, apoptosis takes more time to develop [23]. For
instance, exogenous or endogenous BDNF could exert neuroprotection
through stimulation of neuronal survival and inhibition of apoptosis in
this period. BDNF might be involved in the endogenous neuroprotective
response after PA, as BDNF mRNA levels detected at 48 h survival were
signiﬁcantly increased in all brain areas compared to naïve animals in a
newborn piglet HIE model [24]. Furthermore, exogenous BDNF was
found neuroprotective in a rat neonatal hypoxic-ischemic brain injury
model [13]. Neuroprotection elicited by intracerebroventrical admin-
istration of BDNF to postnatal day 7 rat pups was causally linked to
pronounced and rapid increases in the phosphorylation/activation of
ERK and Akt kinases lasting up to at least 12 h. Furthermore, ERK ac-
tivation was speciﬁcally shown to reduce apoptotic neuronal death
assessed with cleaved caspase 3 immunohistochemistry [13].
Fig. 2. Core temperature (Panel A), oxygen saturation (Panel B), heart rate (Panel C), and mean arterial blood pressure (MABP) (Panel D) data in the control and in the asphyxia groups
during the ﬁrst 24 h survival period. There were no signiﬁcant diﬀerences between the groups in the monitored parameters either in the ﬁrst or the second (data not shown) 24 h period.
Data are shown as mean ± S.E.M.
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In addition to BDNF, other growth factors such as basic ﬁbroblast
growth factor have been identiﬁed as a factor promoting cell survival
and neurogenesis, through activation of the ERK pathway [25,26]. In
addition, Cohen-Armon et al. demonstrated that ERK2 phosphorylation
can be modulated by PolyADP-ribose polymerase-1 (PARP-1) which
catalyze a posttranslational modiﬁcation of nuclear proteins by
polyADP-ribosylation [27]. PARP-1 activation could play a role in our
model as it has been found to be induced by hypoxia in newborn piglets
[28]. The importance of the activation of the PI3K/Akt signaling
pathway has been demonstrated in an adult rat stroke model, where
cerebral infarct was elicited with permanent middle cerebral artery
occlusion (pMCAO). Again, BDNF could reduce infarct size that was
associated with the phosphorylation of Akt. Wortmannin, a selective
PI3K inhibitor, could reverse the increment in p-Akt level and the af-
forded neuroprotection [29]. The transient elevation in p-Akt levels was
also noted in adult mice within hours of MCAO, and this endogenous
activation was regarded as neuroprotective [30].
Our current study yielded markedly diﬀerent results concerning the
phosphorylation levels of both ERK and Akt. Unlike in the previously
cited adult or P7 neonatal rodent studies [13,29,30], ERK and Akt
Fig. 3. Ratio of phosphorylated (P-ERK, P-Akt) and levels of total ERK and Akt in the cerebral cortex of the diﬀerent experimental groups (bar graphs) with representative blots. There
were no signiﬁcant diﬀerences among the diﬀerent groups. Untreated – untreated group; Control, C – time control animals without asphyxia; A – asphyxia group, 24 h–48 h – length of
survival. Data are shown as mean ± S.E.M.
Fig. 4. Ratio of phosphorylated (P-ERK, P-Akt) and levels of total ERK and Akt in the normoxic, non-asphyxiated cerebral cortex after inhibition with the MEK inhibitor U0126 and the
Akt1/2 kinase inhibitor A-6730, respectively. Both inhibitor signiﬁcantly reduced phosphorylation compared to the contralateral untreated side. *p < 0.05 compared to the untreated
side. Data are shown as mean ± S.E.M.
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phosphorylation was virtually complete also in the cortex of untreated
naïve animals, and it was not changed signiﬁcantly either in the nor-
moxic time controls or the animals subjected to PA for at least 48 h.
This high degree of baseline phosphorylation/activation of untreated
animals was also observed in virtually all of the assessed brain regions,
not only in the neocortex, but also in the hippocampus, the caudate
nucleus, the thalamus, cerebellum, and the medulla oblongata sug-
gesting a general phenomenon. Similarly, high phosphorylation levels
were maintained also at 48 h after asphyxia. Our pharmacological ex-
periments proved that these ﬁndings cannot be simply attributed to
technical limitations. We could show in the neocortex, where local
pharmacological treatment through the closed cranial window was
possible that the MEK and Akt1/2 kinase inhibitors could reduce ra-
pidly and statistically signiﬁcantly the ratio of the phosphorylated
forms of ERK and Akt, respectively. The background of this substantial
diﬀerence is unknown, but one can assume to be associated with the
fact that the piglets in the present study were indeed in the perinatal
period: they were all born< 24 h before the experiments. Vaginal de-
livery even under physiological conditions is associated with mild as-
phyxia and perhaps this physiological amount of cerebral hypoxia is
enough to trigger the observed activation of ERK and Akt. This situation
may be in sharp contrast with most of the neonatal rodent HIE models.
In these models P7–P8 pups are used because brain maturity is closest
to the term human baby at this postnatal age [31]. However, our results
suggest that in these models the eﬀects of delivery on cerebral function
may have already likely faded, and the activation levels of ERK and Akt
are signiﬁcantly diﬀerent from the immediate perinatal period. These
results question the eﬃcacy of therapeutic interventions aiming to ac-
tivate these antiapoptotic signaling pathways to obtain neuroprotec-
tion. This suggestion is in line with the recent ﬁndings of an elegant
study. Robertson et al. studied melatonin-induced neuroprotection in a
very similar newborn piglet 48 h survival HIE model. Although
melatonin was found neuroprotective, however, signiﬁcant anti-apop-
totic eﬀect of melatonin using cleaved caspase-3 im-
munohistochemistry could not be shown in the cerebral cortex [32].
5. Conclusion
We demonstrated in a translational newborn piglet model of PA/
HIE that the endogenous activations levels of ERK and Akt kinases
critical in antiapoptotic signaling are already high in the cerebral cortex
and all other assessed brain regions under baseline conditions and
would not signiﬁcantly change up to 48 h following asphyxia capable to
induce signiﬁcant neuronal injury. We propose that further activation
of these signaling pathways is diﬃcult, and this limitation should be
taken into consideration when designing rational neuroprotective
treatments to mitigate the long term adverse eﬀects of HIE.
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